Can Histoplasma capsulatum cause a lung mass with hilar adenopathy visible on a Positron Emission Tomography (PET) Computed Tomography (CT) scan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, Histoplasma capsulatum can cause a lung mass with hilar adenopathy that is visible on a PET-CT scan. Histoplasmosis is a fungal infection that primarily affects the lungs and can present as a solitary pulmonary nodule or mass, often accompanied by hilar and mediastinal lymphadenopathy. On PET-CT imaging, these lesions typically demonstrate increased FDG uptake, which can mimic the appearance of lung cancer or other malignancies. This occurs because the inflammatory response to the fungal infection causes increased metabolic activity in the affected tissues, resulting in FDG avidity. Histoplasmosis is particularly common in certain geographic regions such as the Ohio and Mississippi River valleys in the United States, where the fungus is endemic in soil. Diagnosis typically requires tissue sampling through bronchoscopy, transthoracic needle aspiration, or surgical biopsy, with subsequent fungal cultures or histopathological examination. Treatment depends on the severity of infection but often includes antifungal medications such as itraconazole (200-400 mg daily for 6-12 weeks) for mild to moderate disease, or amphotericin B followed by itraconazole for severe cases, as recommended by the Infectious Diseases Society of America 1.

Some key points to consider in the management of histoplasmosis include:

  • The use of liposomal amphotericin B (3.0 mg/kg daily) for 1–2 weeks, followed by oral itraconazole (200 mg 3 times daily for 3 days and then 200 mg twice daily for a total of at least 12 months) for moderately severe to severe disease 1.
  • The importance of monitoring blood levels of itraconazole to ensure adequate drug exposure 1.
  • The role of antigen levels in monitoring for relapse during and after therapy 1.
  • The potential for immune reconstitution inflammatory syndrome in patients with AIDS, although this is rare and usually not severe 1.

Overall, the management of histoplasmosis requires a comprehensive approach that takes into account the severity of the infection, the patient's underlying health status, and the potential for complications and relapse.

From the Research

Histoplasma Capsulatum Infection

  • Histoplasma capsulatum is a fungal organism that can cause systemic histoplasmosis, which may present with a range of symptoms, including lung masses and hilar adenopathy 2, 3.
  • The infection can be asymptomatic in healthy immunocompetent individuals, but it can cause severe disease in immunocompromised individuals, particularly those with pre-existing structural lung disease 2, 4.

Imaging Findings

  • Imaging findings, such as pulmonary focal infiltrates, cavitary nodules, mediastinal, and hilar lymphadenopathy, are common in histoplasmosis 3, 5.
  • A "flip-flop fungus" sign, characterized by greater FDG uptake in draining lymph nodes in comparison with the associated lung nodule, can be seen on [18F]FDG-PET/CT scans, which can help differentiate histoplasmosis from malignant disease 5.

Diagnosis and Treatment

  • Diagnosis of histoplasmosis can be challenging, particularly in non-endemic regions, and may require a combination of clinical, laboratory, and imaging findings 5, 6, 4.
  • Treatment of histoplasmosis typically involves antifungal therapy, such as itraconazole, and may require long courses of treatment 2, 4.

Specific Findings on PET CT Scan

  • Histoplasma capsulatum can cause a lung mass with hilar adenopathy visible on a Positron Emission Tomography (PET) Computed Tomography (CT) scan, as seen in cases of chronic cavitary pulmonary histoplasmosis and disseminated histoplasmosis 2, 3, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.